Selected publications
-
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: Results of a median 3-year follow-up of COMFORT-I.
Haematologica.
2015
Academic Article
GET IT
Times cited: 138 -
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
Haematologica.
2014
Academic Article
GET IT
Times cited: 23 -
Efficacy, safety and survival with ruxolitinib in patients with smyelofibrosis: Results of a median 2-year follow-up of COMFORT-I.
Haematologica.
2013
Academic Article
GET IT
Times cited: 116 -
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: A randomized, double-blind, placebo-controlled trial.
Journal of Clinical Oncology.
2013
Academic Article
GET IT
Times cited: 114 -
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
New England Journal of Medicine.
2012
Academic Article
GET IT
Times cited: 1044